Merging Experimental Design and Nanotechnology for the Development of Optimized Simvastatin Spanlastics: A Promising Combined Strategy for Augmenting the Suppression of Various Human Cancer Cells

Simvastatin (SMV) is an antihyperlipidemic agent that has been investigated as a possible anti-cancer agent. An obstacle to malignant tumor therapy using drugs is the delivery of adequate levels to the cancer cells while minimizing side effects following their systemic administration. To circumvent...

Descripción completa

Detalles Bibliográficos
Autores principales: Badr-Eldin, Shaimaa M., Aldawsari, Hibah M., Alhakamy, Nabil A., Fahmy, Usama A., Ahmed, Osama A. A., Neamatallah, Thikryat, Tima, Singkome, Almaghrabi, Raghad H., Alkudsi, Fayda M., Alamoudi, Asmaa A., Alzahrani, Amjad A., Kotta, Sabna, Al-hejaili, Omar D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143367/
https://www.ncbi.nlm.nih.gov/pubmed/35631609
http://dx.doi.org/10.3390/pharmaceutics14051024
_version_ 1784715788684361728
author Badr-Eldin, Shaimaa M.
Aldawsari, Hibah M.
Alhakamy, Nabil A.
Fahmy, Usama A.
Ahmed, Osama A. A.
Neamatallah, Thikryat
Tima, Singkome
Almaghrabi, Raghad H.
Alkudsi, Fayda M.
Alamoudi, Asmaa A.
Alzahrani, Amjad A.
Kotta, Sabna
Al-hejaili, Omar D.
author_facet Badr-Eldin, Shaimaa M.
Aldawsari, Hibah M.
Alhakamy, Nabil A.
Fahmy, Usama A.
Ahmed, Osama A. A.
Neamatallah, Thikryat
Tima, Singkome
Almaghrabi, Raghad H.
Alkudsi, Fayda M.
Alamoudi, Asmaa A.
Alzahrani, Amjad A.
Kotta, Sabna
Al-hejaili, Omar D.
author_sort Badr-Eldin, Shaimaa M.
collection PubMed
description Simvastatin (SMV) is an antihyperlipidemic agent that has been investigated as a possible anti-cancer agent. An obstacle to malignant tumor therapy using drugs is the delivery of adequate levels to the cancer cells while minimizing side effects following their systemic administration. To circumvent this challenge, the researchers directed towards the field of nanotechnology to benefit from the nano-size of the formulation in passively targeting the tumor cells. Thus, our study aimed at investigating the potential of a combined mixture–process variable design for optimization of SMV spanlastics (SMV-SPNs) with minimized particle size and maximized zeta potential to enhance the anticancer activity of the drug. The study investigated the effects of Span(®) 20 and Tween(®) 80 as mixture components and sonication time as a process variable on particle size, polydispersity index, and zeta potential as responses. SPNs were prepared using an ethanol injection method. Combining the predicted optimized variables’ levels is supposed to achieve the set goals with a desirability of 0.821. The optimized spanlastics exhibited a measured globule size of 128.50 nm, PDI of 0.329, and ZP of −29.11 mV. The percentage relative error between predicted responses and the observed ones were less than 5% for the three responses, indicating the optimization technique credibility. A significant improvement in the cytotoxicity of the optimized formulation against three different cancerous cell lines was observed in comparison with SMV. The inhibitory concentration (IC(50)) values of MCF-7, HCT-116, and HEPG2 were found to be 0.89, 0.39, and 0.06 μM at 24 h incubation. The enhanced cytotoxicity could be assigned to the possible improved permeation and preferential build-up within the cancerous cells by virtue of the minimized size. These findings imply that SMV-SPNs could be an ideal strategy to combat cancer.
format Online
Article
Text
id pubmed-9143367
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91433672022-05-29 Merging Experimental Design and Nanotechnology for the Development of Optimized Simvastatin Spanlastics: A Promising Combined Strategy for Augmenting the Suppression of Various Human Cancer Cells Badr-Eldin, Shaimaa M. Aldawsari, Hibah M. Alhakamy, Nabil A. Fahmy, Usama A. Ahmed, Osama A. A. Neamatallah, Thikryat Tima, Singkome Almaghrabi, Raghad H. Alkudsi, Fayda M. Alamoudi, Asmaa A. Alzahrani, Amjad A. Kotta, Sabna Al-hejaili, Omar D. Pharmaceutics Article Simvastatin (SMV) is an antihyperlipidemic agent that has been investigated as a possible anti-cancer agent. An obstacle to malignant tumor therapy using drugs is the delivery of adequate levels to the cancer cells while minimizing side effects following their systemic administration. To circumvent this challenge, the researchers directed towards the field of nanotechnology to benefit from the nano-size of the formulation in passively targeting the tumor cells. Thus, our study aimed at investigating the potential of a combined mixture–process variable design for optimization of SMV spanlastics (SMV-SPNs) with minimized particle size and maximized zeta potential to enhance the anticancer activity of the drug. The study investigated the effects of Span(®) 20 and Tween(®) 80 as mixture components and sonication time as a process variable on particle size, polydispersity index, and zeta potential as responses. SPNs were prepared using an ethanol injection method. Combining the predicted optimized variables’ levels is supposed to achieve the set goals with a desirability of 0.821. The optimized spanlastics exhibited a measured globule size of 128.50 nm, PDI of 0.329, and ZP of −29.11 mV. The percentage relative error between predicted responses and the observed ones were less than 5% for the three responses, indicating the optimization technique credibility. A significant improvement in the cytotoxicity of the optimized formulation against three different cancerous cell lines was observed in comparison with SMV. The inhibitory concentration (IC(50)) values of MCF-7, HCT-116, and HEPG2 were found to be 0.89, 0.39, and 0.06 μM at 24 h incubation. The enhanced cytotoxicity could be assigned to the possible improved permeation and preferential build-up within the cancerous cells by virtue of the minimized size. These findings imply that SMV-SPNs could be an ideal strategy to combat cancer. MDPI 2022-05-09 /pmc/articles/PMC9143367/ /pubmed/35631609 http://dx.doi.org/10.3390/pharmaceutics14051024 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Badr-Eldin, Shaimaa M.
Aldawsari, Hibah M.
Alhakamy, Nabil A.
Fahmy, Usama A.
Ahmed, Osama A. A.
Neamatallah, Thikryat
Tima, Singkome
Almaghrabi, Raghad H.
Alkudsi, Fayda M.
Alamoudi, Asmaa A.
Alzahrani, Amjad A.
Kotta, Sabna
Al-hejaili, Omar D.
Merging Experimental Design and Nanotechnology for the Development of Optimized Simvastatin Spanlastics: A Promising Combined Strategy for Augmenting the Suppression of Various Human Cancer Cells
title Merging Experimental Design and Nanotechnology for the Development of Optimized Simvastatin Spanlastics: A Promising Combined Strategy for Augmenting the Suppression of Various Human Cancer Cells
title_full Merging Experimental Design and Nanotechnology for the Development of Optimized Simvastatin Spanlastics: A Promising Combined Strategy for Augmenting the Suppression of Various Human Cancer Cells
title_fullStr Merging Experimental Design and Nanotechnology for the Development of Optimized Simvastatin Spanlastics: A Promising Combined Strategy for Augmenting the Suppression of Various Human Cancer Cells
title_full_unstemmed Merging Experimental Design and Nanotechnology for the Development of Optimized Simvastatin Spanlastics: A Promising Combined Strategy for Augmenting the Suppression of Various Human Cancer Cells
title_short Merging Experimental Design and Nanotechnology for the Development of Optimized Simvastatin Spanlastics: A Promising Combined Strategy for Augmenting the Suppression of Various Human Cancer Cells
title_sort merging experimental design and nanotechnology for the development of optimized simvastatin spanlastics: a promising combined strategy for augmenting the suppression of various human cancer cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143367/
https://www.ncbi.nlm.nih.gov/pubmed/35631609
http://dx.doi.org/10.3390/pharmaceutics14051024
work_keys_str_mv AT badreldinshaimaam mergingexperimentaldesignandnanotechnologyforthedevelopmentofoptimizedsimvastatinspanlasticsapromisingcombinedstrategyforaugmentingthesuppressionofvarioushumancancercells
AT aldawsarihibahm mergingexperimentaldesignandnanotechnologyforthedevelopmentofoptimizedsimvastatinspanlasticsapromisingcombinedstrategyforaugmentingthesuppressionofvarioushumancancercells
AT alhakamynabila mergingexperimentaldesignandnanotechnologyforthedevelopmentofoptimizedsimvastatinspanlasticsapromisingcombinedstrategyforaugmentingthesuppressionofvarioushumancancercells
AT fahmyusamaa mergingexperimentaldesignandnanotechnologyforthedevelopmentofoptimizedsimvastatinspanlasticsapromisingcombinedstrategyforaugmentingthesuppressionofvarioushumancancercells
AT ahmedosamaaa mergingexperimentaldesignandnanotechnologyforthedevelopmentofoptimizedsimvastatinspanlasticsapromisingcombinedstrategyforaugmentingthesuppressionofvarioushumancancercells
AT neamatallahthikryat mergingexperimentaldesignandnanotechnologyforthedevelopmentofoptimizedsimvastatinspanlasticsapromisingcombinedstrategyforaugmentingthesuppressionofvarioushumancancercells
AT timasingkome mergingexperimentaldesignandnanotechnologyforthedevelopmentofoptimizedsimvastatinspanlasticsapromisingcombinedstrategyforaugmentingthesuppressionofvarioushumancancercells
AT almaghrabiraghadh mergingexperimentaldesignandnanotechnologyforthedevelopmentofoptimizedsimvastatinspanlasticsapromisingcombinedstrategyforaugmentingthesuppressionofvarioushumancancercells
AT alkudsifaydam mergingexperimentaldesignandnanotechnologyforthedevelopmentofoptimizedsimvastatinspanlasticsapromisingcombinedstrategyforaugmentingthesuppressionofvarioushumancancercells
AT alamoudiasmaaa mergingexperimentaldesignandnanotechnologyforthedevelopmentofoptimizedsimvastatinspanlasticsapromisingcombinedstrategyforaugmentingthesuppressionofvarioushumancancercells
AT alzahraniamjada mergingexperimentaldesignandnanotechnologyforthedevelopmentofoptimizedsimvastatinspanlasticsapromisingcombinedstrategyforaugmentingthesuppressionofvarioushumancancercells
AT kottasabna mergingexperimentaldesignandnanotechnologyforthedevelopmentofoptimizedsimvastatinspanlasticsapromisingcombinedstrategyforaugmentingthesuppressionofvarioushumancancercells
AT alhejailiomard mergingexperimentaldesignandnanotechnologyforthedevelopmentofoptimizedsimvastatinspanlasticsapromisingcombinedstrategyforaugmentingthesuppressionofvarioushumancancercells